Navigation Links
The Role of Central Laboratories in Alzheimer’s Disease Research, a New Global Cliniacal Trials Webinar Hosted by Xtalks
Date:11/18/2013

Toronto, Canada (PRWEB) November 18, 2013

Recently, major changes were made in the diagnostic criteria for Alzheimer’s disease and encompass the latest findings in the field, which is helping to facilitate more clinical research. Already, the usual clinical interview can be coupled with brain imaging testing approved by the FDA for the diagnosis of Alzheimer’s disease in live patients. Several disease-modifying or disease-preventing therapies are also appearing in clinical trials. Central laboratories can play a key role in clinical trials for Alzheimer’s disease drug development by assisting with patient population identification and by detecting, at an early stage, drugs that are likely to fail, leading to important time and costs savings.

Join us for this webinar that will be addressing how central laboratories can support clinical trials through quality testing within the context of the latest advances in Alzheimer’s disease research.

For more information about this online seminar or to visit this webinar’s homepage, go to http://xtalks.com/central-laboratories-in-alzheimers-research.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://www.xtalks.com
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. LabCentral Adds Eppendorf as a Major Sponsor of the Cambridge Launchpad for Life Science Startups
2. The Arrow Group of Animal Hospitals in Central Arizona Partners with Vet-Stem, Inc. to Bring Stem Cell Therapy to Their Patients
3. ResearchMoz.us: Private Healthcare Market - Investigation, Study, Size, Share in Central Europe and Poland and Poland 2013
4. Congresso ESH 2013, dallo studio SEVITENSION nuove evidenze sullefficacia della combinazione fissa olmesartan/amlodipina vs. perindopril/amlodipina nel controllo della pressione arteriosa centrale
5. Endpoint Based Protocol Development: A Central Laboratory Perspective + Microbiology Case Study, New Life Science Webinar Hosted by Xtalks
6. Central Nervous System (CNS) Biomarkers Market: 2017 Forecast in New Research Report at ReportsnReports.com
7. Site Quality Management to Optimize Risk-Based and Centralized Monitoring, New Life Science Webinar Hosted by Xtalks
8. ‘Timely’ new undergrad program in photonics at University of Central Florida applauded by SPIE
9. BioHealth Innovation, Inc. Forms Commercial Relevance Advisory Board to Help Advance Market-Relevant Innovations in Central Maryland
10. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
11. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/17/2014)... Dec. 17, 2014   Synageva BioPharma Corp. ... therapeutic products for rare disorders, announced today its presentation ... in San Francisco, CA. ... Executive Officer, will present on Monday, January 12, 2015, ... will be webcast live and may be accessed from ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... TEL-AVIV, Israel and PORTLAND, Oregon, October 2 , ... Exertion Identified,Abnormalities of Cardiovascular Function and Might be Useful ... Treatment in,Clinical Practice and Trials , ... Exercise Cardiac,Output (ECO(R)) stress test protocol for chronic heart ...
... --Company to Host Conference Call-- , CALGARY, Oct. 2 ... announced that it has reached an agreement with the ... Protocol Assessment (SPA) process for the design of a ... and carboplatin in patients with platinum-refractory head and neck ...
... ... Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) October 2, 2009 -- ... series specifically for biotech and specialty pharma companies. The new series includes Situational Leadership ...
Cached Biology Technology:New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure 2New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Perceptum Group Announces New Situational Leadership V Series 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... the University of California, Riverside have unlocked the molecular ... such as leaves to develop in a jigsaw-like pattern, ... findings were published in today's edition of the journal ... biology at the UCR's Center for Plant Cell Biology ...
... Northwestern University Feinberg School of Medicine played a ... of Abraxane (paclitaxel protein-bound particles for injectable suspension), ... "The approval means that women with metastatic breast ... associated with solvents and will no longer need ...
... that human leprosy infections provide for study of human ... warning system prompts a rapid immune response by two ... why, when threatened by microbes like the leprosy bug, ... but in other cases yields to a dangerous, spreading ...
Cached Biology News:Nanoparticle Breast Cancer Drug Approved by FDA 2Leprosy microbes lead scientists to immune discovery 2
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
HSPBP1 Antibody...
... CRE-bla HEK 293T cell line contains the ... cAMP response element (CRE). To obtain the ... into HEK 293T cells by lentivirus. Subsequent ... responsive to forskolin stimulation (Figure 1). The ...
Biology Products: